SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SolarEdge Technologies, Inc. – SEDG
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SolarEdge Technologies, Inc. (“SolarEdge” or the “Company”) (NASDAQ: SEDG). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OTLK
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers. The class action, filed in the United States District Court
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DISH Network Corporation – DISH
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of DISH Network Corporation (“DISH” or the “Company”) (NASDAQ: DISH). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Holley Inc. f/k/a Empower Ltd. – (HLLY; HLLY.WT; EMPW; EMPW-WT)
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Holley Inc. f/k/a Empower Ltd. (“Holley” or the “Company”) (NYSE: HLLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 8
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placeboResults also showed statistically significant rapid and sustained reductions i
Statement by the Prime Minister on Poland’s National Independence Day
OTTAWA, ON, Nov. 11, 2023 /CNW/ – The Prime Minister, Justin Trudeau, today issued the following statement on Poland’s National Independence Day: “Today, I join Polish communities in Canada and around the world in celebrating the anniversary of Poland’s independence. “O
LAS VEGAS TACO BELL CANTINA REVS UP FOR THE BIG RACE WITH TIGHT TURNS AND TACOS WATCH PARTY
Limited spots with track views on Saturday, November 18 LAS VEGAS, Nov. 11, 2023 /PRNewswire/ — World Class racing is revving up for an exhilarating debut in the streets of Las Vegas, and the iconic Las Vegas Taco Bell Cantina, owned by Diversified Restaurant Group, will be the ultimate desti
Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
This first presentation of non-human primate (NHP) data highlights the potential of Chroma’s epigenetic editors to achieve specific and robust results after a single administration, without cutting or nicking the DNA In NHPs, Chroma’s epigenetic editor achieved efficient reductions in bl
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kenvue Inc. – KVUE
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adobe, Inc. – ADBE
NEW YORK, Nov. 11, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Adobe, Inc. (“Adobe” or the “Company”) (NASDAQ: ADBE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 798